According to the United States Renal Data Systems, the most common initial ESRD treatment modality among children overall continues to be haemodialysis (50.4%). Since 2006, 81% of incident paediatric ESRD patients have started haemodialysis with a central venous catheter. The initiation of haemodialysis with a catheter is observed in the majority of children and adolescents. This data clearly exhibits vascular access as an ever increasing field, particularly in paediatric population.

The major focus of this new research report has been on the diversified application of vascular access devices in the treatment of paediatric malignancies, which is becoming progressively more complex, implying the adoption of multimodal therapies. Vascular Access Devices is one of the new tools that enable the neonatologist and paediatric surgeon to provide ongoing therapy for very ill babies, at the same time allowing invasive monitoring of the clinical condition. Also, vascular access is a pre-requisite for the management of paediatric surgical patients.

According to new report “Global Vascular Access Devices Market Outlook 2022” by RNCOS, vascular access is frequently required in hospitalized children for a variety of clinical indications. In addition, various vascular access options are available to the physicians handling paediatric population to meet the required treatment needs. It may vary from short-term or temporary needs to long-term or even permanent access. Recently, the increasing use of venous access devices including long term, short term and midterm has provided a major improvement in the treatment of children affected by onco-hematological disease. Central venous access devices are also amongst the major components essential for care in the paediatric population, requiring intravenous therapy in the management of acute and chronic diseases.

Conclusively, the recent technological advancements, such as minimally invasive procedures, new devices and novel materials, have rapidly gained attention and have expanded during the last few years for clinical use in the paediatric population.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM872.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.